Jump to navigation
About
Mission and Values
Leadership Team
Board of Directors
Medical Advisors
Focus
Hyperoxaluria
Systemic Oxalosis
Hyperuricemia
Publications
Products
Reloxaliase
ALLN-346
Pipeline
FAQs
Investors
Overview
News Releases
Events and Presentations
Stock Information
Analyst Coverage
Corporate Governance
SEC Filings
Shareholder Services
Careers
Contact
Home
Dedicated to Treating Patients
With Rare and Severe
Metabolic Diseases
Utilizing the GI Tract
to Reduce the Burden
of Metabolic Disease
Understanding
Metabolic Diseases
that Affect the Kidney
News
February 24, 2020
Allena Pharmaceuticals to Present at 40th Annual Cowen & Co. Health Care Conference
Read more
about Allena Pharmaceuticals to Present at 40th Annual Cowen & Co. Health Care Conference
February 12, 2020
Allena Pharmaceuticals Announces Streamlined Design for URIROX-2, Second Pivotal Clinical Trial of Reloxaliase for Enteric Hyperoxaluria
Read more
about Allena Pharmaceuticals Announces Streamlined Design for URIROX-2, Second Pivotal Clinical Trial of Reloxaliase for Enteric Hyperoxaluria
December 4, 2019
Allena Pharmaceuticals Provides Updates on Reloxaliase Development Program and Corporate Activities
Read more
about Allena Pharmaceuticals Provides Updates on Reloxaliase Development Program and Corporate Activities
